Local Spotlights
New Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival
In a groundbreaking Phase 3 trial, an experimental drug nearly doubled the median overall survival for patients with advanced pancreatic cancer, a disease notoriously resistant to treatment.
Caitlin O'Malley·May 31, 2026
